The PE Ratio as of November 2024 (TTM) for Zentalis Pharmaceuticals, Inc. (ZNTL) is -1.29

According to Zentalis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.29. This represents a change of -123.97% compared to the average of 5.38 of the last 4 quarters.

Zentalis Pharmaceuticals, Inc. (ZNTL) Historical PE Ratio (quarterly & annually)

How has ZNTL PE Ratio performed in the past?

The mean historical PE Ratio of Zentalis Pharmaceuticals, Inc. over the last ten years is -14.31. The current -1.29 PE Ratio has changed 801.33% with respect to the historical average. Over the past ten years (40 quarters), ZNTL's PE Ratio was at its highest in in the March 2024 quarter at 28.40. The PE Ratio was at its lowest in in the September 2021 quarter at -177.33.

Zentalis Pharmaceuticals, Inc. (ZNTL) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Zentalis Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Zentalis Pharmaceuticals, Inc. (ZNTL) Average PE Ratio

How has ZNTL PE Ratio performed in the past?

The current PE Ratio of Zentalis Pharmaceuticals, Inc. (ZNTL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Zentalis Pharmaceuticals, Inc. (ZNTL) PE Ratio vs. Peers

How is ZNTL’s PE Ratio compared to its peers?

Zentalis Pharmaceuticals, Inc.’s PE Ratio is greater than Sana Biotechnology, Inc. (-2.01), greater than Olema Pharmaceuticals, Inc. (-4.10), greater than Cullinan Oncology, Inc. (-5.10), greater than aTyr Pharma, Inc. (-2.33), greater than Gracell Biotechnologies Inc. (-29.05), greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than Monte Rosa Therapeutics, Inc. (-5.83), greater than Design Therapeutics, Inc. (-6.66), greater than Erasca, Inc. (-4.79), greater than Day One Biopharmaceuticals, Inc. (-15.73), greater than Inozyme Pharma, Inc. (-1.84), greater than Syndax Pharmaceuticals, Inc. (-4.63), less than Protagonist Therapeutics, Inc. (16.80), greater than Revolution Medicines, Inc. (-16.70), greater than Blueprint Medicines Corporation (-46.60), greater than Kymera Therapeutics, Inc. (-20.45), greater than iTeos Therapeutics, Inc. (-2.96), greater than Icosavax, Inc. (-15.78), greater than Mirati Therapeutics, Inc. (-11.26), greater than VectivBio Holding AG (-7.94), greater than Annexon, Inc. (-6.12),

Build a custom stock screener for Zentalis Pharmaceuticals, Inc. (ZNTL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zentalis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Zentalis Pharmaceuticals, Inc. (ZNTL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Zentalis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.